A0100 - PSMA PET for high risk prostate cancer patient: a cost effective strategy von Al-Mitwalli, A., Mubarak, M.M, Rashid, M.R, Jefferies, M.J, Kandaswamy, G.K, Powles, A.P

Volltext

PSMA PET for high risk prostate cancer patient: a cost effective strategy von Al-Mitwalli, A., Mubarak, M.M, Rashid, M.R, Jefferies, M.J, Kandaswamy, G.K, Powles, A.P

Volltext

Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma von Sonpavde, Guru P., Sternberg, Cora N., Loriot, Yohann, Marabelle, Aurelien, Lee, Jae Lyun, Fléchon, Aude, Roubaud, Guilhem, Pouessel, Damien, Zagonel, Vittorina, Calabro, Fabio, Banna, Giuseppe L., Shin, Sang Joon, Vera-Badillo, Francisco E., Powles, Thomas, Hellmis, Eva, Miranda, Paulo A.P., Lima, Ana Rita, Emeribe, Ugochi, Oh, Sun Min, Hotte, Sebastien J.

Volltext

697O A phase III, randomized, open-label study of first-line durvalumab (D) with or without tremelimumab (T) vs standard of care chemotherapy in patients with unresectable, locally... von Powles, T.B., van der Heijden, M.S., Castellano Gauna, D., Loriot, Y., Galsky, M.D., Petrylak, D.P., Ogawa, O., Park, S.H., Necchi, A., Lee, J-L., De Giorgi, U., Bögemann, M., Bamias, A., Fay, A.P., Duran, I., Angra, N., Gupta, A.K., He, P., Levin, W., Bellmunt, J.

Volltext

AMINO (HYDROXYETHOXYMETHYL) PURINE: A NEW WELL-ABSORBED PRODRUG OF ACYCLOVIR von Selby, P., Blake, S., Mbidde, E.K., Hickmott, E., Powles, R.L., Stolle, K., Mcelwain, T.J., Whiteman, P.D., Fiddian, A.P.

Volltext